Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 C3 activator and hypocomplementaemia in a "healthy" woman.

Literature DB >> 1252817

C3 activator and hypocomplementaemia in a "healthy" woman.

A Karstorp.

Abstract

Entities: Species

Mesh：

Substances：

Year: 1976 PMID： 1252817 PMCID： PMC1638888 DOI： 10.1136/bmj.1.6008.501-a

Source DB: PubMed Journal: Br Med J ISSN： 0007-1447

× No keyword cloud information.

4 in total

1. Serum C'3 lytic system in patients with glomerulonephritis.

Authors: R E Spitzer; E H Vallota; J Forristal; E Sudora; A Stitzel; N C Davis; C D West
Journal: Science Date: 1969-04-25 Impact factor: 47.728

2. Increased susceptibility to infection in a patient with type II essential hypercatabolism of C3.

Authors: C A Alper; K J Bloch; F S Rosen
Journal: N Engl J Med Date: 1973-03-22 Impact factor: 91.245

3. The C3 nephritic factor and membranoproliferative nephritis: correlation of serum levels of the nephritic factor with C3 levels, with therapy, and with progression of the disease.

Authors: E H Vallota; J Forristal; N C Davis; C D West
Journal: J Pediatr Date: 1972-06 Impact factor: 4.406

4. Complement studies in membrano-proliferative glomerulonephritis.

Authors: D K Peters; A Martin; A Weinstein; J S Cameron; T M Barratt; C S Ogg; P J Lachmann
Journal: Clin Exp Immunol Date: 1972-07 Impact factor: 4.330

4 in total

3 in total

C3 activator and hypocomplementaemia in a "healthy" woman.

1. Serum C'3 lytic system in patients with glomerulonephritis.

2. Increased susceptibility to infection in a patient with type II essential hypercatabolism of C3.

3. The C3 nephritic factor and membranoproliferative nephritis: correlation of serum levels of the nephritic factor with C3 levels, with therapy, and with progression of the disease.

4. Complement studies in membrano-proliferative glomerulonephritis.

1. Identification of nephritic factor as an immunoglobulin.

2. Requirements for the production of high-titre C3 nephritic factor (NEF) antibody in vitro.

3. Causes of alternative pathway dysregulation in dense deposit disease.